Prucalopride in treatment of functional chronic constipation
Abstract
The aim of review. To carry out analysis of literature devoted to efficacy assessment of new prokinetic drug – 5-НТ4-receptor agonist prucalopride in treatment of patients with chronic functional constipation.
Original points. Being an agonist of 5-НТ4- receptors, prucalopride stimulates motility of the large intestine and promotes more frequent bowel movements. Numerous studies confirmed that on a background of prucalopride intake in a dose of 2 or 4 mg for 4-12 wks in patients with chronic constipation defecation frequency increases and quality of life improves. It is important, that the agent has no cardiotoxic effect and does not increase the length of Q–T interval.
Conclusion. Prucalopride can be recommended for treatment of functional chronic constipation, first of all – in women, resistant to laxatives.
References
1. Bengtsson M., Ohlsson B. Psychological well-being and symptoms in women with chronic constipation treated with sodium picosulphate // Gastroenterol. Nurs. – 2005. – Vol. 28. – P. 3–12.
2. Breier M.R., Prins N.H., Schuurkes J.A. Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs // Neurogastroenterol. Motil. – 2001. – Vol. 13. – P. 465–472.
3. Boyce M., Kerstens R., Beyens G. et al. Cardiovascular safety of prucalopride in healthy subjects: results from a randomised, double-blind, placebo-controlled, cross-over trial // Gut. – 2008. – Vol. 57 (suppl. II). – Abstracts – A282.
4. Camilleri M., Robinson P., Kerstens R., Vandeplassche M. Safety and adverse event profiles of oral prucalopride: are similar in elderly and adult patients with chronic constipation // Chicago: DDW, 2011. –Abstracts – Mo1304.
5. Dennison C., Prasad M., Lloid A. et al. The health-related quality of life and economic burden of constipation // Pharmacoeconomics. – 2005. – Vol. 23. – P. 461–467.
6. Dubois D., Kerstens R., Vandeplasscshe L., Tack J. Symptom severity and quality of life in patients with chronic constipation: pooled results from three identical randomized placebo-controlled trials with prucalopride // Gut. – 2008. – Vol. 57 (suppl. II). – Abstracts – A178.
7. Emmanuel A.V., Kerstens R., Vandeplassche L.M. Prucalopride improves bowel function and colonic transit time in patients with constipation // Chicago: DDW, 2011. – Abstracts – Mo1326.
8. Ford A. An evidence-based systematic review on the management of irritable bowel symdrome // Am. J. Gastroenterol. – 2009. – Vol. 104 (suppl. 1). – P.1–28.
9. Galandiuk S., Ryks A., Ausma J., Vandeplassche L. A two-period, double-blind, placebo-controlled study to evaluate the effects of re-treatment of prucalopride (resolor) on efficacy and safety in patients with chronic constipation // Gut. – 2008. – Vol. 57 (suppl. II). – Abstracts – A86.
10. Higgins P.D., Johanson J.F. Epidemiology of constipation in North America: a systemic review // Am. J. Gastroenterol. – 1999. – Vol. 99. – P. 750–759.
11. Johanson J.F., Kralstein J. Chronic constipation: a survey of the patient perspective // Aliment. Pharmacol. Ther. – 2007. – Vol. 25. – P. 599–608.
12. Kamm M.A., Emmanuel A.V., Kerstens R., Vandeplassche L. Double-blind, placebo-controlled, cross-over, multiple (N=1) trial to evaluate the effects of pruсalopride in patients with chronic intestinal pseudo-obstruction (CIP) // Gut. – 2008. – Vol. 57 (suppl. II). – Abstracts – A284.
13. Longstreth G.F., Thompson W.G., Chey W.D. et al. Functional bowel disorders // Gastroenterology. – 2006. – Vol. 130. – P.1480–1491.
14. Mueller-Lissner S., Ryk A., Kerstens R., Vandeplassche L. Pooled efficacy data in elderly patients treated with prucalopride for chronic constipation // Gut. – 2008. – Vol. 57 (suppl. II). – Abstracts – A180.
15. Nichols T.W., Beyens G., Ausma J., Kerstens R. A double-blind, placebo-controlled, dose-finding trial to evaluate the efficacy and safety of prucalopride in patients with chronic constipation // Gut. – 2008. – Vol. 57 (suppl. II). – Abstracts – A283.
16. Ouigley E., Vandeplassche L., Kerstens R., Ausna J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12-week, randomized, double-blind,
17. placebo-controlled study // Aliment. Pharmacol. Ther. – 2009. – Vol. 29. – P. 315–328.
18. Stanghellini V., Kerstens R.., Vandeplassche L.M. Sustained efficacy of oral prucalopride in patients with chronic constipation // Gut. – 2008. – Vol. 57 (suppl. II). – Abstracts – A284.
19. Stanghellini V., Vandeplassche L.M., Kerstens R., Janssens M. The rеlation between adverse events on day 1 and pharmacodynamic effects on day 1 of treatment with pruсalopride // Chicago: DDW, 2011. – Abstracts– Mo1336.19.
20. Stewart W.F., Liberman J.N., Sandler R.S. et al. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features // Am. J. Gastroenterol. – 1999. – Vol. 94. – P. 3530–3540.
21. Tachtatzis Ph.M., Kham U., Kelly A. et al. Prucalopride for constipation in a tertiary care setting: real life experience // Chicago: DDW, 2011. – Abstracts – Mo1323.
22. Tack J., van Outryve M., Beyens G. et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives // Gut. – 2009. –Vоl. 58. – P. 357–365.
23. Tack J.F., Kerstens R., Vandeplassche L.M. Efficacy and safety of oral prucalopride in female patients with chronic constipation: pooled data of 3 pivotal trials // Chicago: DDW, 2011. – Abstracts – Mo1335.
24. Tonini M., Pace F. Drugs acting on serotonin receptors for the treatment of functional GI disorders // Gastrointestinal Pharmacology and Therapeutics / Eds. Scarpignato C., di Mario F. – Basel: Karger, 2006. – P. 96–113.
25. Van de Velde V., Ausma J., Vandeplassche L.M. Pharmacokinetics of pruсalopride (Resolor) in man // Gut. – 2008. – Vol. 57 (suppl. II). – Abstracts – A282.
26. Yost K.J., Haan M.N., Levine R.A. et al. Comparing SF-36 scores across three groups of women with different health profiles // Qual. Life Res. – 2005. – Vol. 14. – P. 1251–1261.
Review
For citations:
Sheptulin A.A. Prucalopride in treatment of functional chronic constipation. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2012;22(1):9-13. (In Russ.)
Views:
82
Email this article 
